Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Laboratory Corporation of America Holdings (LH Quick QuoteLH - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, Laboratory Corporation has a trailing twelve months PE ratio of 17.3, as you can see in the chart below:

This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 compares in at about 20.9. If we focus on the stock’s long-term PE trend, the current level puts Laboratory Corporation’s current PE ratio slightly above its midpoint (which is 15.7) over the past five years.

Further, the stock’s PE also compares favorably with the industry’s trailing twelve months PE ratio, which stands at 18.9. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.

We should also point out that Laboratory Corporation has a forward PE ratio (price relative to this year’s earnings) of just 14.7, so it is fair to say that a slightly more value-oriented path may be ahead for Laboratory Corporation’s stock in the near term too.   

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, Laboratory Corporation has a P/S ratio of about 1.7. This is significantly lower than the S&P 500 average, which comes in at 3.4 right now. Also, as we can see in the chart below, this is slightly below the highs for this stock in particular over the past few years.

If anything, this suggests some level of undervalued trading—at least compared to historical norms.   

Broad Value Outlook

In aggregate, Laboratory Corporation currently has a Value Style Score of A, putting it into the top 20% of all stocks we cover from this look. This makes LH a solid choice for value investors, and some of its other key metrics make this pretty clear too.

For example, the PEG ratio for Laboratory Corporation is just 1.4, a level that is slightly lower than the industry average of 1.8. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Additionally, its P/CF ratio (another great indicator of value) comes in at 11.3, which is somewhat better than the industry average of 12.4. Clearly, LH is a solid choice on the value front from multiple angles.

What About the Stock Overall?

Though Laboratory Corporation might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of A and a Momentum score of B. This gives LH a VGM score—or its overarching fundamental grade—of A. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been encouraging. The current quarter has seen nine estimates go higher in the past sixty days, compared to none lower, while the full year estimate has seen eleven upward and one downward revisions in the same time period.

This has had a favorable impact on the consensus estimate, as the current quarter consensus estimate has risen about 8.2% in the past two months, while the full year estimate has improved nearly 9.1%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

The stock holds a Zacks Rank #3 (Hold), which indicates expectations of in-line performance from the company in the near term. However, Laboratory Corporation is enjoying bullish analyst sentiment, as indicated by the positive estimate revisions, and this works in the company’s favor.

Bottom Line

Laboratory Corporation is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (bottom 17% out of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past one year, the sector has clearly underperformed the broader market, as you can see below:

Despite positive estimate revision activity, investors should wait for broader factors and industry trends to turn around first.  When they do, this stock could be a compelling value pick.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>